Sales & Earnings In Brief
This article was originally published in The Tan Sheet
Executive Summary
Schering-Plough: Double-digit gains by OTC Claritin and sun care triggered a strong second quarter for the consumer health division, up 19% to $317 mil. Claritin sales jumped 22% to $117 mil. due to trade inventory adjustments in the year-ago quarter. Sun care revenue totaled $78 mil. (up 60%) as a result of the "timing of orders and shipments, coupled with favorable weather conditions," and foot care rose 7% to $89 mil. Schering has "good work underway" on new Coppertone and Dr. Scholl's extensions, CEO Fred Hassan tells analysts July 21. The solid consumer health results were more than offset by continuing struggles in Rx pharmaceuticals, spending on the FDA consent decree and restructuring costs. Consolidated sales fell 7% to $2.15 bil. and the firm reported a net loss of $65 mil...
You may also be interested in...
Claritin Growth Plateaus As Schering Moves Ahead With Consent Decree
Sales of Schering-Plough's Claritin (loratadine) appear to have leveled off following a strong 2003 campaign for the over-the-counter antihistamine
Claritin Growth Plateaus As Schering Moves Ahead With Consent Decree
Sales of Schering-Plough's Claritin (loratadine) appear to have leveled off following a strong 2003 campaign for the over-the-counter antihistamine
Claritin Growth Plateaus As Schering Moves Ahead With Consent Decree
Sales of Schering-Plough's Claritin (loratadine) appear to have leveled off following a strong 2003 campaign for the over-the-counter antihistamine